Visit Store
Visit Store
Keep up with what’s new in medicine and healthcare publishing.
Elsevier Spotlight

Oral anticoagulation (OAC) is superior to dual antiplatelet therapy (DAT) in preventing stroke in patients with atrial fibrillation (AF), but DAT is superior to OAC in preventing stent thrombosis and ischemic events after percutaneous coronary intervention (PCI). In the approximately 5-10% of patients with AF who undergo PCI, many are given treatment with both of these therapies, the so-called triple antithrombotic therapy (TAT) approach. Golwala et al conducted a systematic review and meta-analysis of phase 3 randomized trials that compared DAT vs. TAT in patients with AF following PCI. A total of 5317 patients from 4 trials (WOEST, ISAR-TRIPLE, PIONEER AF-PCI, RE-DUAL PCI) were included. Mean follow-up ranged from 9 to 14 months and mean age was 70.9 years in the DAT group and 71.1 years in the TAT group. About half of each arm underwent PCI for acute coronary syndrome and the remainder underwent PCI for non-ACS indications. MORE

News & Articles

Difficulties with harvest of the Semitendinosus (ST) and, if necessary, Gracilis are vexing for many Orthopaedic Surgeons. It is the primary force that drives many surgeons to use allografts despite the fact the results of allografts are clearly substantially inferior to autografts. I used hamstrings from the beginning of my career in 1985 for open ACL reconstruction. I used large incisions and harvest was easy. MORE

Elsevier Spotlight

Oral anticoagulation (OAC) is superior to dual antiplatelet therapy (DAT) in preventing stroke in patients with atrial fibrillation (AF), but DAT is superior to OAC in preventing stent thrombosis and ischemic events after percutaneous coronary intervention (PCI). In the approximately 5-10% of patients with AF who undergo PCI, many are given treatment with both of these therapies, the so-called triple antithrombotic therapy (TAT) approach. Golwala et al conducted a systematic review and meta-analysis of phase 3 randomized trials that compared DAT vs. TAT in patients with AF following PCI. A total of 5317 patients from 4 trials (WOEST, ISAR-TRIPLE, PIONEER AF-PCI, RE-DUAL PCI) were included. Mean follow-up ranged from 9 to 14 months and mean age was 70.9 years in the DAT group and 71.1 years in the TAT group. About half of each arm underwent PCI for acute coronary syndrome and the remainder underwent PCI for non-ACS indications. MORE

Reviews

This book remains very popular among medical students who are preparing for the boards. Dr. Goljan is a seasoned educator in pathology and a very talented writer of board review books. This is not a book for first time pathology learners, but rather a review of the most important features of different entities with excellent and very helpful images. MORE

Expert Perspectives

Explore the latest resources and learn from authors in your field.